Newborn screening for hemoglobinopathies in California

Area of Science:

• Genetics
• Pediatrics
• Public Health

Background:

• Newborn screening (NBS) for hemoglobinopathies in California aids early diagnosis and care.
• NBS reduces mortality in children with sickle cell disease.
• Increased prevalence of hemoglobin disorders due to immigration necessitates updated screening.

Purpose of the Study:

• To evaluate the California hemoglobinopathy screening program.
• To analyze the incidence and types of hemoglobin disorders identified.
• To assess the effectiveness of current screening methods.

Main Methods:

• High-performance liquid chromatography (HPLC) for primary screening.
• Electrophoresis and genotyping for confirmatory testing.
• Analysis of 530,000 newborn samples screened annually.

Main Results:

• 0.05% of newborns required confirmatory testing.
• Sickle cell disease, alpha-thalassemia, and beta-thalassemia were most common.
• Confirmatory testing altered initial screening in 5% of cases, identifying 25 rare genotypes across diverse ethnicities.

Conclusions:

• The California program accurately diagnoses hemoglobinopathies.
• Rising incidence of diverse mutations demands new screening, counseling, and management strategies.